

Amendments to the Specification

The specification is being amended to correct typographical and clerical errors. No new subject matter is being added.

Please replace the paragraph on page 5, at line 18, with the following rewritten paragraph:

Further the present invention provides for a method or of ameliorating chronic allograft rejection by administering an amount of CSA and 2-CDA effective sufficient to suppress the B-cell mediated response to an allograft. In one embodiment, the allograft organ is a heart and the B-cell mediated response is one or a combination of mononuclear cell infiltration in the myocardium, myocardial fibrosis, and intimal proliferation of smooth muscle cells.

Please replace the paragraph on page 10, at line 7, with the following rewritten paragraph:

In one embodiment, the therapeutically effective amount of 2-chlorodeoxyadenosine 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week. Suitably, the dose of 2-chlorodeoxyadenosine 2-chlorodeoxyadenosine is about 1 mg per kilogram of recipient body mass per week, divided into one or more doses per week. In another embodiment, about 1.5 mg of 2-chlorodeoxyadenosine 2-chlorodeoxyadenosine per kilogram of allograft recipient body mass is administered about every three weeks in one or more doses. In another embodiment, about 3 mg of 2-chlorodeoxyadenosine 2-chlorodeoxyadenosine per kilogram of allograft recipient body mass is administered about every three weeks in one or more doses.

Please replace the paragraph on page 19, at line 5, with the following rewritten paragraph: